Europeiska unionen - svenska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multipelt myelom - antineoplastiska medel - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiska medel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - bikalutamid - filmdragerad tablett - 150 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; bikalutamid 150 mg aktiv substans - bikalutamid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - bikalutamid - filmdragerad tablett - 150 mg - bikalutamid 150 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - bikalutamid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - bikalutamid - filmdragerad tablett - 150 mg - natriumlaurilsulfat hjälpämne; bikalutamid 150 mg aktiv substans; laktosmonohydrat hjälpämne - bikalutamid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - bikalutamid - filmdragerad tablett - 50 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; bikalutamid 50 mg aktiv substans - bikalutamid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - bikalutamid - filmdragerad tablett - 50 mg - bikalutamid 50 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - bikalutamid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - bikalutamid - filmdragerad tablett - 50 mg - natriumlaurilsulfat hjälpämne; bikalutamid 50 mg aktiv substans; laktosmonohydrat hjälpämne